Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 479, Everolimus, Panitumumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Everolimus, AMG 479, Panitumumab | EXPERIMENTAL | Dose Escalation Cohort #, Subjects, Everolimus, AMG 479 1. 3-6 subjects, Study drug administered per dose level 2. 3-6 subjects, Study drug administered per dose level Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab 3. 3-6 subjects, Study drug administered per dose level 4. 3-6 subjects, Study drug administered per dose level Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level |
| Name | Type | Description |
|---|---|---|
| AMG 479, Everolimus, Panitumumab | DRUG | Dose Escalation Cohort #, Subjects, Everolimus, AMG 479 1. 3-6 subjects, Study drug administered per dose level 2. 3-6 subjects, Study drug administered per dose level Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab 3. 3-6 subjects, Study drug administered per dose level 4. 3-6 subjects, Study drug administered per dose level Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level |
Inclusion Criteria: 1. Histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapies, or for which no standard therapies exist. Disease must be measurable by RECIST criteria. For the NSCLC expanded cohort only: Only histologically proven adenocarci...
AMG 479 is an investigational oncology drug being studied for multiple cancer types, including adenocarcinoma of the pancreas, advanced malignancy, Askin's tumors, breast cancer, advanced solid tumors, and non-small cell lung cancer. It has been evaluated in clinical trials for pancreatic cancer and Ewing's family tumors.
AMG 479 is being developed by ImmunityBio, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IBRX. The drug is an investigational small molecule oncology therapy.
AMG 479 has completed Phase 3 clinical development. It remains an investigational drug and is not approved by the FDA. The drug has completed two trials, including a Phase 3 study in metastatic pancreatic cancer.
AMG 479 has been studied in completed trials including NCT01231347, a Phase 3 study of gemcitabine plus AMG 479 in metastatic adenocarcinoma of the pancreas with 800 participants, and NCT00563680, a Phase 2 study in relapsed or refractory Ewing's family tumors.
AMG 479 is also known by the name ganitumab. It is an investigational drug being developed by ImmunityBio, Inc. for oncology indications including pancreatic cancer and advanced solid tumors.